Collapse all
The Business Model Canvas reveals a high-value, specialized B2B model that shifts oncology from reactive to predictive treatment. Success depends on deep integration with genomic data providers and clinical validation within top-tier research hospitals to prove the 'critical interval' theory.
3 Genomic Sequencing Labs Partnerships with labs to obtain high-fidelity mutation rate data required for the predictive algorithm. Academic Medical Centers Institutions like MSKCC to conduct clinical trials validating the tool's predictive accuracy against actual resistance timelines. Pharmaceutical R&D Companies like Roche to align the tool with the timing of second-line therapy deployment. 3 Algorithm Refinement Developing the mathematical model that converts spontaneous mutation rates into a temporal 'critical interval' forecast. Clinical Validation Running retrospective and prospective studies to prove that switching therapies based on the tool improves patient outcomes. Regulatory Compliance Securing FDA/EMA clearance as a Software as a Medical Device (SaMD) for clinical decision support. 3 Proprietary Predictive Model The mathematical framework relating mutation rates to the probability of resistant phenotype emergence. Oncology Data Sets Large-scale longitudinal data on tumor mutation rates and the timing of drug resistance. Bioinformatics Talent Specialists capable of bridging the gap between theoretical mutation mathematics and clinical software. 3 Predictive Resistance Timing Provides oncologists with a specific window of time to switch therapies before resistant cells reach a critical threshold. Optimized Therapy Switching Reduces the 'treatment gap' where patients are on ineffective drugs while waiting for resistance to be clinically detected. Combination Therapy Guidance Identifies the optimal moment to introduce combination treatments to preemptively suppress resistant clones. 2 Clinical Co-Development Working closely with lead oncologists at Mayo Clinic to refine the UI/UX for real-world clinical workflows. Evidence-Based Trust Maintaining credibility through peer-reviewed publications demonstrating the tool's predictive power. 3 EMR Integration Integrating the tool directly into Electronic Medical Record systems used by oncology departments. Medical Conferences Presenting findings at ASCO and AACR to reach key opinion leaders in precision oncology. Pharma Partnerships Bundling the tool with specific drug regimens as a companion diagnostic for timing therapy switches. 3 Tertiary Cancer Centers High-volume research hospitals like Mayo Clinic and MSKCC treating complex, mutation-prone tumors. Biopharmaceutical Companies Companies like Roche seeking to improve the efficacy and timing of their oncology drug portfolios. Precision Medicine Clinics Specialized practices focusing on genomic-driven personalized treatment plans. 3 R&D and Bio-computation High costs associated with the mathematical modeling and computational power for mutation analysis. Clinical Trial Expenses Significant investment required to validate the 'critical interval' in human patient cohorts. Regulatory Filing Costs Legal and administrative costs for FDA/EMA certification as a medical device. 3 Per-Patient Licensing Fee A fee charged to clinics for every patient analyzed to predict their resistance window. Enterprise SaaS Subscription Annual recurring revenue from large hospital networks for access to the predictive platform. Pharma R&D Partnerships Milestone payments and royalties from pharma companies using the tool to optimize drug trial timing. The idea identifies specific high-value beneficiaries like Roche and Mayo Clinic, making it appropriate to map out the value proposition and revenue streams. · Generated 2026-08-18 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated